Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Classical hematology 1

Conditions

Ovarian Neoplasms 1Iron Deficiencies 1Carcinoma, Ovarian Epithelial 1Anemia, Iron-Deficiency 1Anemia 1

Interventions

Epoetin Alfa 9Darbepoetin alfa 5epoetin beta 3telapristone acetate 2fludarabine phosphate 2fludarabine 2Cyclophosphamide 2Carboplatin 2Busulfan 2AP 1903 reagent 2ACE-011 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2venetoclax 1vactosertib 1trametinib 1thymoglobulin 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1peginesatide 1palbociclib 1olaparib 1niraparib 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1hematide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Anemia × Ferric Oxide, Saccharated × Clear all
NCT03933813 2023-01-05

Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

University of Wisconsin, Madison

Phase 1/2 Terminated
9 enrolled
Classical hematologyGynecologic

Carcinoma, Ovarian Epithelial, Iron Deficiencies, Anemia, Ovarian Neoplasms, Anemia, Iron-Deficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡